Kapil Dhingra
Independent DirectorDr. Kapil Dhingra, M.B.B.S., M.D., Ph.D., is Supervisory Board Member at LES LABORATOIRES SERVIER, SAS since March 2022. He serves as Member of Scientific Advisory Board since May 2026 at Byondis B.V. He serves as Member of Oncology Clinical Advisory Board at Step Pharma SAS. He served as Director at CARGO Therapeutics, Inc. since April 2024 until August 18, 2025. He served as an Advisor of Forbion Capital Partners B. V. He is the Co-Founder, Chairman of SAB and Director of Kirilys Therapeutics, Inc. Dr. Dhingra serves as an Independent Director at Mariana Oncology, Inc. (formerly known as Curie Therapeutics, Inc.) since February 2022. Dr. Dhingra serves as Member of Strategic Advisory Board at SCTbio a. s. (formerly known as Sotio a. s.). He was Strategic Advisory Board Member at IO Biotech, Inc. until March 31, 2026. He is Member of Scientific Advisory Board at IO Biotech ApS. Dr. Dhingra serves as Strategic Advisor since March 2022 at Medicenna Therapeutics Corp. He serves as an Independent Non-Executive Chairman and was Non-Executive Chairman at Lava Therapeutics N. V. since January 2021. He serves as a Member of Clinical & Scientific Advisory Board at eFFECTOR Therapeutics, Inc. He held a Clinical Affiliate appointment at Memorial Sloan Kettering Cancer Center since 2000 until 2008. Dr. Dhingra founded KAPital Consulting LLC in June 2008. Dr. Dhingra served as Director of Five Prime Therapeutics, Inc. since December 2, 2015 until April 16, 2021. Dr. Dhingra serves as an Independent Director at Black Diamond Therapeutics, Inc. since January 2021. Dr. Dhingra has been Head of KAPital Consulting LLC since June 2008 and serves as its Managing Member. He serves as a Consultant at Oncos Therapeutics Ltd. Dr. Dhingra provided strategic development leadership resulting in a track record of global oncology drug approvals, including numerous indications for Herceptin(R), MabThera(R), Xeloda(R), Bondronat(R), Tarceva(R) and Avastin(R). He has experience in oncology clinical research and drug development, including at Roche Pharmaceuticals, where he played a key role in the expansion of Roche Oncology. Dr. Dhingra has been active in oncology clinical research. He serves as Member of Scientific Advisory Board at Tarveda Therapeutics, Inc. During his tenure at Hoffmann-La Roche from 1999 to 2008, he built the largest oncology clinical development department in the industry. In 1999, he joined Hoffmann-La Roche as Clinical Science Leader. Throughout his industry career, he maintained an active faculty appointment, initially at Indiana University School of Medicine from 1997 to 1999 as Clinical Associate Professor and at Memorial Sloan Kettering Cancer Center from 2000 to 2008. Dr. Dhingra was a faculty Member at The University of Texas M. D. Anderson Cancer Center from 1989 to 1996, where he conducted clinical and laboratory research and also providing direct patient care responsibilities. He worked at Eli Lilly & Co. From 1999 to June 2008, Dr. Dhingra worked in positions at Roche, as Head Oncology Disease Biology Leadership Team and Head of Oncology Clinical Development. He served as Vice President of Oncology at Roche since 2002. He played a key role in the dramatic expansion of Roche oncology enterprise. In 2007, he was appointed Leader of Disease Biology Leadership Team, within Roche's R&D model. From 1996 to 1999, Dr. Dhingra served at Eli Lilly and Company as Senior Clinical Research Physician with responsibility for the global development strategy of a novel Selective Estrogen Receptor Modulator. He was the Chairman of Exosome Diagnostics, Inc. since April 2013 until August 2018. He serves as the Chairman of Clinical Advisory Board at Karus Therapeutics Limited. Dr. Dhingra served as an Independent Non-Executive Director of Advanced Accelerator Applications S. A. from April 2014 to January 2018. Dr. Dhingra was a Non-Executive Director of Algeta ASA since April 2010 until March 2014. He was a Director of YM Biosciences Inc. since November 20, 2012 until February 2013. He serves as a Member of BoD of biotechs: Blincyto, Xofigo, Imlygic and Lutathera. He was Director of Exosome Diagnostics, Inc. since March 28, 2012 until August 2018. Dr. Dhingra serves as a Director of SARC. Dr. Dhingra had been a Director at Autolus Therapeutics Plc. since August 2014 until December 31, 2023. He served as Director of Autolus Ltd from October 20, 2014 until June 15, 2018. He has been a Director of MEDIAN Technologies S. A. since 2017. He served as a Director of EpiTherapeutics ApS from January 2014 to May 2015. He served as Director of Coferon, Inc. from January 2009 to June 2012. Dr. Dhingra served as a Director of Micromet, Inc. from February 2009 to March 2, 2012 and a Director of BioVex, Inc. from 2009 to 2011. He has been Member of Oncology Scientific Advisory Board at Asana BioSciences, LLC since January 04, 2016. Dr. Dhingra serves on the Editorial Board of Future Drugs and the Editorial Advisory Board of R&D Directions. He served as a Member of the Scientific Advisory Board at Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited). He has been a Member of the Clinical Advisory Board at Oncos Therapeutics Ltd. since July 2012. He advises Forbion on opportunities in the oncology space. He serves as a Member of Scientific Advisory Board of Intellikine LLC. He serves as a Director at Replimune Group, Inc. (Formerly, Replimune Limited) since July 2017. He served as Member of Scientific & Clinical Advisory Board at Heat Biologics, Inc. since October 2015. Dr. Dhingra served as a Member of the Clinical Advisory Board at Biocon Limited. In his academic career, he received several research grants from the National Cancer Institute as well as from major oncology pharmaceutical and biotechnology companies and built an impressive record of publications in peer-reviewed journals. Dr. Dhingra has authored or co-authored more than 100 publications and abstracts. Dr. Dhingra is a medical oncologist and a physician-scientist with a proven track record in academic research, patient care and drug development. He served as Vice President, Head of the Oncology Disease Biology Leadership Team and Head of Oncology Clinical Development at Hoffmann-La Roche (Roche) from May1999 to August 2008, during which he led numerous drug approvals, including Herceptin, Tarceva, Xeloda, Zelboraf, Perjeta and Avastin. Prior to joining Roche, he worked in the oncology clinical development group at Eli Lilly and Company. He is a Member of the NCI Experimental Therapeutics Panel. He completed his residency in internal medicine at Lincoln Medical and Mental Health Center, New York Medical College and completed his fellowship in hematology and oncology at Emory University School of Medicine. Dr. Dhingra obtained his medical oncology training at Emory University from 1986 to 1988 and has performed postgraduate work at the All India Institute of Medical Services, the Lincoln Medical and Mental Health Cente
Positions
- Company NameBlack Diamond Therapeutics, Inc.Stock CodeBDTXPositionIndependent DirectorColleagues
- MAMark A. VellecaCEO, President & Chairman
- BHBrent Hatzis-SchochCOO & General Counsel
- SYSergey YurasovChief Medical Officer
- EBElizabeth BuckCo-Founder & Chief Scientific Officer
- EJErika JonesPrincipal Financial Officer, Principal Accounting Officer, SVP of Finance & Corporate Controller
- ABAli BehbahaniIndependent Director
- GEGarry E. MenzelIndependent Director
- SKSamarth KulkarniLead Independent Director
